JP7069138B2 - 抗Ｃ１ｓ抗体およびその使用方法 - Google Patents

抗Ｃ１ｓ抗体およびその使用方法 Download PDF

Info

Publication number
JP7069138B2
JP7069138B2 JP2019519690A JP2019519690A JP7069138B2 JP 7069138 B2 JP7069138 B2 JP 7069138B2 JP 2019519690 A JP2019519690 A JP 2019519690A JP 2019519690 A JP2019519690 A JP 2019519690A JP 7069138 B2 JP7069138 B2 JP 7069138B2
Authority
JP
Japan
Prior art keywords
antibody
seq
region
amino acid
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019519690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502996A (ja
JP2020502996A5 (https=
Inventor
サンディップ・パニッカー
グラハム・パリー
ナンシー・イー・スタグリアーノ
Original Assignee
バイオベラティブ・ユーエスエイ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオベラティブ・ユーエスエイ・インコーポレイテッド filed Critical バイオベラティブ・ユーエスエイ・インコーポレイテッド
Publication of JP2020502996A publication Critical patent/JP2020502996A/ja
Publication of JP2020502996A5 publication Critical patent/JP2020502996A5/ja
Priority to JP2022073972A priority Critical patent/JP7420864B2/ja
Application granted granted Critical
Publication of JP7069138B2 publication Critical patent/JP7069138B2/ja
Priority to JP2024002216A priority patent/JP2024038319A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019519690A 2016-10-12 2017-10-12 抗Ｃ１ｓ抗体およびその使用方法 Active JP7069138B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022073972A JP7420864B2 (ja) 2016-10-12 2022-04-28 抗Ｃ１ｓ抗体およびその使用方法
JP2024002216A JP2024038319A (ja) 2016-10-12 2024-01-11 抗Ｃ１ｓ抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662407390P 2016-10-12 2016-10-12
US62/407,390 2016-10-12
PCT/US2017/056349 WO2018071676A1 (en) 2016-10-12 2017-10-12 Anti-c1s antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022073972A Division JP7420864B2 (ja) 2016-10-12 2022-04-28 抗Ｃ１ｓ抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2020502996A JP2020502996A (ja) 2020-01-30
JP2020502996A5 JP2020502996A5 (https=) 2020-11-12
JP7069138B2 true JP7069138B2 (ja) 2022-05-17

Family

ID=61906346

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019519690A Active JP7069138B2 (ja) 2016-10-12 2017-10-12 抗Ｃ１ｓ抗体およびその使用方法
JP2022073972A Active JP7420864B2 (ja) 2016-10-12 2022-04-28 抗Ｃ１ｓ抗体およびその使用方法
JP2024002216A Withdrawn JP2024038319A (ja) 2016-10-12 2024-01-11 抗Ｃ１ｓ抗体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022073972A Active JP7420864B2 (ja) 2016-10-12 2022-04-28 抗Ｃ１ｓ抗体およびその使用方法
JP2024002216A Withdrawn JP2024038319A (ja) 2016-10-12 2024-01-11 抗Ｃ１ｓ抗体およびその使用方法

Country Status (35)

Country Link
US (3) US20200048332A1 (https=)
EP (2) EP3525583B8 (https=)
JP (3) JP7069138B2 (https=)
KR (3) KR20250171438A (https=)
CN (2) CN110300520B (https=)
AR (1) AR110677A1 (https=)
AU (3) AU2017341766A1 (https=)
BR (1) BR112019007309A2 (https=)
CA (1) CA3040253A1 (https=)
CL (1) CL2019000975A1 (https=)
CO (1) CO2019004741A2 (https=)
CR (1) CR20190223A (https=)
DK (1) DK3525583T3 (https=)
DO (1) DOP2019000085A (https=)
EA (1) EA201990884A1 (https=)
EC (1) ECSP19033211A (https=)
ES (1) ES3049257T3 (https=)
FI (1) FI3525583T3 (https=)
HR (1) HRP20251304T1 (https=)
HU (1) HUE073475T2 (https=)
IL (3) IL265957B2 (https=)
LT (1) LT3525583T (https=)
MX (2) MX2019004259A (https=)
MY (1) MY198182A (https=)
PE (1) PE20191031A1 (https=)
PH (1) PH12019500789A1 (https=)
PL (1) PL3525583T3 (https=)
PT (1) PT3525583T (https=)
RS (1) RS67326B1 (https=)
SG (1) SG11201903012RA (https=)
SI (1) SI3525583T1 (https=)
TN (1) TN2019000109A1 (https=)
TW (3) TWI773695B (https=)
WO (1) WO2018071676A1 (https=)
ZA (1) ZA201902247B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024038319A (ja) * 2016-10-12 2024-03-19 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗Ｃ１ｓ抗体およびその使用方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
EP4640703A3 (en) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
EP4696320A2 (en) 2019-05-15 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibody
EP4139350A4 (en) * 2020-04-20 2024-04-24 Genzyme Corporation Humanized anti-complement factor bb antibodies and uses thereof
CN115427445A (zh) * 2020-04-22 2022-12-02 彻莫马布有限公司 使用抗ccl24抗体的治疗方法
EP4149486A1 (en) * 2020-05-11 2023-03-22 Genentech, Inc. Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
IL300376A (en) * 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
CA3155939A1 (en) * 2021-04-30 2022-10-30 Upm-Kymmene Corporation A method for freeze-drying a hydrogel composition and a freeze-dried hydrogel composition
CN117769434A (zh) 2021-05-20 2024-03-26 黛安瑟斯医疗运营公司 与C1s结合的抗体和其用途
CN120757653A (zh) 2021-07-13 2025-10-10 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
US20240117021A1 (en) 2022-06-15 2024-04-11 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
CA3260415A1 (en) 2022-06-24 2023-12-28 Bioverativ Usa Inc. METHODS OF TREATMENT FOR COMPLEMENT-MEDICATED DISEASES
WO2024112734A1 (en) 2022-11-21 2024-05-30 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof
KR20250158063A (ko) 2023-03-16 2025-11-05 젠자임 코포레이션 건식 연령-관련 황반 변성의 치료

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012510282A (ja) 2008-12-03 2012-05-10 ゲンマブ エー／エス 定常領域の中に改変を有する抗体変種
JP2016503400A (ja) 2012-10-25 2016-02-04 トゥルー・ノース・セラピューティクス・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
JP2016505240A (ja) 2012-11-02 2016-02-25 トゥルー・ノース・セラピューティクス・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
JP2016520313A (ja) 2013-05-23 2016-07-14 ブロテイオ ファーマ ビーヴィＢｒｏｔｅｉｏ Ｐｈａｒｍａ Ｂ．Ｖ． ヒト補体因子ｃ２に結合する結合分子、及び、その使用。

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
CA1276103C (en) 1984-10-02 1990-11-13 Fumiaki Taguchi Substance-conjugated complement component c1q
JPS61271455A (ja) 1985-05-28 1986-12-01 Olympus Optical Co Ltd 免疫学的分析方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
PT716611E (pt) 1993-09-01 2002-06-28 Sanquin Bloedvoorziening Metodo para reduzir a lesao do miocardio durante um enfarte do miocardio agudo
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
KR100551104B1 (ko) 1994-12-09 2006-02-09 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
JP4437192B2 (ja) 1998-02-20 2010-03-24 タノックス インコーポレイテッド 補体活性化阻害剤
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
US6492403B1 (en) 1999-02-09 2002-12-10 3-Dimensional Pharmaceuticals, Inc. Methods of treating C1s-mediated diseases and conditions and compositions thereof
AU4369000A (en) 1999-04-26 2000-11-10 Duke University Inhibition of complement action
AU6929100A (en) 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
EP1250594A4 (en) 2000-01-19 2003-05-07 Biotransplant Inc PORC UNABLE TO TRANSMIT PORCINE ENDOGENEOUS RETROVIRUS, AND USES THEREOF
CA2398707C (en) 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US6998468B2 (en) 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
EP1349874A2 (en) 2000-06-21 2003-10-08 ZymoGenetics, Inc. Peptide and polypeptide inhibitors of complement c1s
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
WO2003009803A2 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
WO2003042361A2 (en) 2001-11-09 2003-05-22 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP1463802A1 (en) 2002-01-11 2004-10-06 GTC Biotherapeutics, Inc. Method and system for fusion and activation following nuclear transfer in reconstructed embryos
US20080206242A1 (en) 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
JP4601426B2 (ja) 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US9715692B1 (en) 2003-04-11 2017-07-25 Facebook, Inc. System for managing bids for pay-per-click search engines
EP2266606B1 (en) 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7923010B2 (en) 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
PT1737891E (pt) * 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
ES2631127T3 (es) 2004-06-10 2017-08-28 Omeros Corporation Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
KR20080002832A (ko) 2005-03-16 2008-01-04 얀센 파마슈티카 엔.브이. 보체 매개성 질병 및 이상을 치료하기 위한 신규한 티오펜설폭시민
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
CA2654440C (en) 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
CN101218295B (zh) 2005-07-05 2010-12-08 株式会社钟化 甲基丙烯酸类树脂组合物
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
JP5219819B2 (ja) 2005-10-21 2013-06-26 カタリスト・バイオサイエンシーズ・インコーポレイテッド 補体活性化を阻害する修飾プロテアーゼ
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
WO2007070375A2 (en) 2005-12-09 2007-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
NZ571791A (en) 2006-03-08 2012-03-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
NZ615012A (en) 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
CN103849629B (zh) 2006-06-21 2017-06-09 尤尼克尔Ip股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体
US9388235B2 (en) 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
EP2073898A1 (en) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
CN101679219B (zh) 2006-12-19 2014-08-13 港大科桥有限公司 合成离子通道
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
US8236307B2 (en) 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
US7788398B2 (en) * 2007-08-08 2010-08-31 Swarmcast, Inc. Media player plug-in installation techniques
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20110081347A1 (en) 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
WO2009151634A1 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US20110311550A1 (en) 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CA2740192C (en) 2008-12-01 2019-12-31 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CA2766565A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
DK2488203T3 (en) 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
WO2011102342A1 (ja) 2010-02-16 2011-08-25 国立大学法人京都工芸繊維大学 抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
ES2615732T3 (es) 2010-03-01 2017-06-08 Alexion Pharmaceuticals, Inc. Composiciones para tratar la enfermedad de Degos
EP2561073B1 (en) 2010-04-23 2016-08-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
CA2799746C (en) 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
EP2648752B1 (en) 2010-12-06 2017-02-15 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
US9505826B2 (en) 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
BR112013025917A2 (pt) 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
JP6127063B2 (ja) 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
JP6081699B2 (ja) 2011-12-28 2017-02-15 雅史 溝上 Ｉｌ−２８ｂの分析方法
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
WO2014119969A1 (ko) * 2013-01-31 2014-08-07 서울대학교 산학협력단 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
EP2997045A4 (en) 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
DK3019240T3 (da) * 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
WO2015084999A1 (en) 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
CN107073113A (zh) 2014-10-18 2017-08-18 辉瑞大药厂 抗il‑7r抗体组合物
CA2981321A1 (en) * 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
MX2017016835A (es) 2015-06-26 2018-08-01 Bioverativ Usa Inc Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios.
CN110300520B (zh) * 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
CR20190468A (es) 2017-03-14 2019-12-17 Bioverativ Usa Inc Métodos para tratar enfermedades y trastornos mediados por completo
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3774892A4 (en) 2018-04-13 2022-02-16 Chugai Seiyaku Kabushiki Kaisha ANTI-COMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
IL300376A (en) 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
WO2022212645A1 (en) 2021-03-31 2022-10-06 Bioverativ Usa Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
US20240117021A1 (en) 2022-06-15 2024-04-11 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
CA3260415A1 (en) 2022-06-24 2023-12-28 Bioverativ Usa Inc. METHODS OF TREATMENT FOR COMPLEMENT-MEDICATED DISEASES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012510282A (ja) 2008-12-03 2012-05-10 ゲンマブ エー／エス 定常領域の中に改変を有する抗体変種
JP2016503400A (ja) 2012-10-25 2016-02-04 トゥルー・ノース・セラピューティクス・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
JP2016505240A (ja) 2012-11-02 2016-02-25 トゥルー・ノース・セラピューティクス・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
JP2016520313A (ja) 2013-05-23 2016-07-14 ブロテイオ ファーマ ビーヴィＢｒｏｔｅｉｏ Ｐｈａｒｍａ Ｂ．Ｖ． ヒト補体因子ｃ２に結合する結合分子、及び、その使用。

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024038319A (ja) * 2016-10-12 2024-03-19 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗Ｃ１ｓ抗体およびその使用方法

Also Published As

Publication number Publication date
CN110300520B (zh) 2022-10-04
US20200048332A1 (en) 2020-02-13
CN116554320A (zh) 2023-08-08
KR20240025715A (ko) 2024-02-27
AU2022205174B2 (en) 2025-08-14
DOP2019000085A (es) 2019-07-31
TN2019000109A1 (en) 2020-10-05
JP2020502996A (ja) 2020-01-30
TW202434298A (zh) 2024-09-01
CL2019000975A1 (es) 2019-10-04
CN110300520A (zh) 2019-10-01
EP4652926A3 (en) 2026-03-18
EP3525583B8 (en) 2025-09-10
CO2019004741A2 (es) 2019-07-31
LT3525583T (lt) 2025-11-10
PT3525583T (pt) 2025-10-22
TW202246327A (zh) 2022-12-01
AR110677A1 (es) 2019-04-24
EA201990884A1 (ru) 2019-10-31
IL265957B1 (en) 2023-12-01
KR102638884B1 (ko) 2024-02-22
MX2024008202A (es) 2024-07-15
JP7420864B2 (ja) 2024-01-23
BR112019007309A2 (pt) 2019-07-02
IL308156B1 (en) 2026-03-01
HUE073475T2 (hu) 2026-01-28
SG11201903012RA (en) 2019-05-30
PL3525583T3 (pl) 2026-01-19
ES3049257T3 (en) 2025-12-15
FI3525583T3 (fi) 2025-10-31
JP2024038319A (ja) 2024-03-19
AU2017341766A1 (en) 2019-05-23
EP3525583A1 (en) 2019-08-21
CA3040253A1 (en) 2018-04-19
WO2018071676A1 (en) 2018-04-19
PH12019500789A1 (en) 2019-07-29
SI3525583T1 (sl) 2025-12-31
AU2025267421A1 (en) 2025-12-04
RS67326B1 (sr) 2025-11-28
TWI846007B (zh) 2024-06-21
US20260092104A1 (en) 2026-04-02
KR20250171438A (ko) 2025-12-08
IL265957B2 (en) 2024-04-01
KR102891406B1 (ko) 2025-11-27
PE20191031A1 (es) 2019-08-05
IL265957A (en) 2019-05-30
US20240076363A1 (en) 2024-03-07
IL326479A (en) 2026-04-01
AU2022205174A1 (en) 2022-09-29
JP2022105114A (ja) 2022-07-12
DK3525583T3 (da) 2025-10-27
CR20190223A (es) 2019-08-21
NZ753111A (en) 2025-06-27
HRP20251304T1 (hr) 2025-12-05
EP3525583B1 (en) 2025-07-23
EP4652926A2 (en) 2025-11-26
US12391750B2 (en) 2025-08-19
IL308156A (en) 2023-12-01
TW201821437A (zh) 2018-06-16
KR20190082783A (ko) 2019-07-10
TWI773695B (zh) 2022-08-11
ZA201902247B (en) 2024-07-31
ECSP19033211A (es) 2019-07-31
MX2019004259A (es) 2019-09-27
MY198182A (en) 2023-08-09
EP3525583A4 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
JP7420864B2 (ja) 抗Ｃ１ｓ抗体およびその使用方法
JP7518114B2 (ja) ヒト化抗Ｃ１ｓ抗体及びその使用方法
HK40013301B (en) Anti-c1s antibodies and methods of use thereof
HK40013301A (en) Anti-c1s antibodies and methods of use thereof
HK40015348A (en) Anti-c1s antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220502

R150 Certificate of patent or registration of utility model

Ref document number: 7069138

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250